Autres langues Alzinova AB

Actions

ALZ

SE0007413455

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 12/10/2026			Varia. 5j.	Varia. 1 janv.
0,4830 ^SEK	+11,29%		+26,27%	-41,74%

08/10	Alzinova AB présente les dernières avancées d’ALZ-101 et de ses diagnostics sanguins lors de la Redeye Neurology Day	CI
08/10	Redeye réitère sa valeur cible de 0,90 couronne pour Alzinova après l’émission de droits préférentiels	FW

Autres langues

08/10	Alzinova: Rights issue subscribed to 86.2%
08/10	Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day
08/10	Alzinova AB Presents Latest Developments In ALZ-101 And Blood-Based Diagnostics At Redeye Neurology Day
08/10	Alzinova: Rights issue completed
07/10	Alzinova announces final outcome of the rights issue
07/10	Alzinova Announces Preliminary Outcome Of The Rights Issue
06/10	Alzinova announces preliminary outcome of the rights issue
02/10	Alzinova Broadens Shareholder Base With New Investor
01/10	Alzinova broadens its shareholder base with a new institutional investor, while its principal shareholder subscribes for its full pro rata share in the ongoing rights issue
01/10	Alzinova : The last day of trading in unit rights in Alzinova's rights issue
01/10	The last day of trading in unit rights in Alzinova’s rights issue
01/10	Alzinova: Supportive early results for diagnostics programme
30/09	Alzinova : completes study with Amsterdam UMC - results support continued development and partnership discussions in blood-based Alzheimer's diagnostics
30/09	Alzinova completes study with Amsterdam UMC – results support continued development and partnership discussions in blood-based Alzheimer’s diagnostics
30/09	Alzinova AB and Amsterdam University Medical Center Complete Study in Blood-Based Alzheimer?S Diagnostics
24/09	Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference
22/09	The subscription period in Alzinovas rights issue of units starts today
21/09	Alzinova Initiates Global Phase Ii Start-Up of Therapeutic Vaccine Alz-101 and Advances Blood-Based Diagnostic Program
21/09	Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need
18/09	Alzinova publishes information memorandum in connection with rights issue of units
11/09	Alzinova: Phase II study update and SEK51 rights issue
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate
10/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million